Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | LDHB | P07195 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22099681 | 0.88 | CSNK1D (0.38) | MIFCSNK1DPIK3CGPARP1 | |
| SCHEMBL17895297 | 0.85 | ADORA2A (0.43) | MIFADORA2AADORA1ADORA3PIK3CG | |
| SCHEMBL17895305 | 0.85 | IKBKB (0.38) | PPM1BMIFLDHALDHBDHODH | |
| SCHEMBL22099685 | 0.83 | IKBKB (0.40) | MIFCSNK1D | |
| SCHEMBL17895187 | 0.81 | BRD4 (0.37) | MIFCSNK1D | |
| SCHEMBL17895206 | 0.81 | MIF (0.39) | MIFADORA2AADORA1ADORA3PIK3CG | |
| SCHEMBL17895108 | 0.81 | MIF (0.39) | MIFADORA2AADORA1PIK3CG | |
| SCHEMBL17895059 | 0.80 | BRD4 (0.40) | — | |
| SCHEMBL17895242 | 0.78 | ADORA2A (0.45) | MIFADORA2AADORA1ADORA3 | |
| SCHEMBL22099676 | 0.77 | KDM4E (0.38) | PPM1BMIFCSNK1DADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | claimed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | claimed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | claimed |
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| EP-3240789-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | Université de Montpellier (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016107895-A1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITE DE MONTPELLIER (FR) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | PPM1B 2798/4885MIF 3073/4885CSNK1D 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.